title: Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation.
abstract: CD30 is a member of the tumor necrosis factor receptor superfamily, which can transduce signals for proliferation, death, or nuclear factor kappa B (NF-kappa B) activation. Investigation of CD30 signaling pathways using a yeast two-hybrid interaction system trapped a cDNA encoding the tumor necrosis factor receptor-associated factor (TRAF)-2 TRAF homology domain. TRAF-1 and TRAF-3 also interacted with CD30, and > 90% of in vitro-translated TRAF-1 or -2, or 50% of TRAF-3, bound to the CD30 cytoplasmic domain. TRAF-1, -2, and -3 bound mostly, but not exclusively, to the carboxyl-terminal 36 residues of CD30. The binding was strongly inhibited by a CD30 oligopeptide centered around a PXQXT (where X is any amino acid) motif shared with CD40 and the Epstein-Barr virus transforming protein LMP1, indicating that this motif in CD30 is an important determinant of TRAF-1, -2 or -3 interaction. At least 15% of TRAF-1, -2, or -3 associated with CD30 when coexpressed in 293 cells. The association was not affected by CD30 cross-linking. However, cross-linking of CD30 activated NF-kappa B. NF-kappa B activation was dependent on the carboxyl-terminal 36 amino acids of CD30 that mediate TRAF association. TRAF-2 has been previously shown to have a unique role in TRAF-mediated NF-kappa B activation, and NF-kappa B activation following CD30 cross-linking was blocked by a dominant negative TRAF-2 mutant. These data indicate that CD30 cross-linking-induced NF-kappa B activation is predominantly TRAF-2-mediated.
authors.affiliation: Department of Internal Medicine III, University of Ulm Medical Center, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Ansieau
authors.forename: I
authors.initials: I
authors.lastname: Scheffrahn
authors.forename: G
authors.initials: G
authors.lastname: Mosialos
authors.forename: H
authors.initials: H
authors.lastname: Brand
authors.forename: J
authors.initials: J
authors.lastname: Duyster
authors.forename: K
authors.initials: K
authors.lastname: Kaye
authors.forename: J
authors.initials: J
authors.lastname: Harada
authors.forename: B
authors.initials: B
authors.lastname: Dougall
authors.forename: G
authors.initials: G
authors.lastname: Hübinger
authors.forename: E
authors.initials: E
authors.lastname: Kieff
authors.forename: F
authors.initials: F
authors.lastname: Herrmann
authors.forename: A
authors.initials: A
authors.lastname: Leutz
authors.forename: H J
authors.initials: HJ
authors.lastname: Gruss
mesh_terms: D000595:Amino Acid Sequence; D002460:Cell Line; D003593:Cytoplasm / Q000378:metabolism; D006801:Humans; D017730:Ki-1 Antigen / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism*; D007700:Kinetics; D008969:Molecular Sequence Data; D016328:NF-kappa B / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D014176:Protein Biosynthesis; D011506:Proteins / Q000737:chemistry / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D017386:Sequence Homology, Amino Acid; D047990:TNF Receptor-Associated Factor 1; D047992:TNF Receptor-Associated Factor 2; D048008:TNF Receptor-Associated Factor 3; D015533:Transcriptional Activation; D014162:Transfection
chemical_list: D017730:Ki-1 Antigen; D016328:NF-kappa B; D011506:Proteins; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D047990:TNF Receptor-Associated Factor 1; D047992:TNF Receptor-Associated Factor 2; D048008:TNF Receptor-Associated Factor 3